9Simerka P,Eur-LEX A.Council recommendation of 8June 2009on an action in the field of rare diseases[EB/OL].http://eurlex.europa.eu/LexUriServ/LexUriServ.
42009/C 151/02, Council Recommendation of 8 June 2009 on an action in the field of rare diseases.
52009 Report on Initiatives and Incentives in the field of rare diseases of the European Union Committee of Experts on Rare Diseases -- Released 21 March 2011, ht- tp://www, eucerd, eu//upload/file/Reports/ 2009ReportInitiativesIncentives. pdf.
6Decision No 1295/1999/EC of The European Par liament and of the council of 29 April 1999 adopting a pro- gramme of Community action on rare disease within the framework for action in the field of public health (1999 to 2003).
7Decision No 1786/2002/EC of the European Par- liament and of the Council of 23 September 2002 adopting a programme of Community action in the field of public health (2003--2008).
8Decision No 1350/2007/EC of the European Par liament and of the Council of 23 October 2007 adopting a second programme of Community action in the field of public health (2008-2013).
2The Orphan Drug Act[ EB/OL]. http://www, ecfr. gov!.
3Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach S L, et al. Incentives for orphan drug research and development in the UnitedStates [ J ]. Orphanet Journal of RareDiseases, 2008, 3(3): 33.
4Jyoti T. Navigating through orphan medicinal product regula- tionsin EU and US-Similarities and differences [ J ]. Regula- tory Toxicology and Pharmacology, 2015, 71 (1) : 63-67.
5Hurwicz L. The design of mechanisms for resource allocation [ J ] . American Economic Review, 1973, 63 (63) : 1-30.
6Haffner M E. Orphan Products: Origins,Progress, and Pros- pects [ J ]. Annual Review of Pharmacology, 1991,31 ( 31 ) : 603-620.
7Drummond M F, Wilson D A, Panos K, et al. Assessing the economicchallenges posed by orphan drugs [ J ]. Interna- tional Journal of Technology Assessment in Health Care, 2007, 23 ( 1 ) : 36-42.
8Blaser D A, Lewtas A J, Ousterhout M M. How To Define Specialty Pharmaceuticals:A Systematic Review[ J]. The A- merican Journal of Pharmacy Benefits, 2010, 2 ( 6 ) : 371-380.
9许焱.我国罕见病药品可及性评价指标体系的构建与影响因素分析[D].武汉:华中科技大学,2012.
10Wesley Yin. Market incentives and pharmaceutical innova- tion [ J ]. Journal of Health Economics, 2008, 27 (4) : 1060-1077.
